Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Bioequivalence study is proposed to be carried out on patients of breast cancer/ ovarian
cancer, who are administrated for Doxorubicin Hydrochloride Liposomal Injection Lipodox® or
Caelyx® in a dose of 50 mg/m2.
Phase:
Phase 1
Details
Lead Sponsor:
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Collaborators:
Cancer Hospital of Guizhou Province Dongguan People's Hospital First Affiliated Hospital of Jinan University Guangzhou Panyu Central Hospital Hunan Cancer Hospital Shantou Central Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The Second Affiliated Hospital of Chongqing Medical University Yuebei People's Hospital Yuncheng Central Hospital Zhejiang Provincial People's Hospital